An analysis of the 3,866 diabetic patients from the CAPRIE study revealed that they had a much higher rate of recurrent ischemic events than nondiabetic patients and that the benefit of clopidogrel over aspirin was amplified in the diabetic cohort. The level of risk and degree of benefit were highest in those diabetic patients who received insulin therapy.